News & Updates

The prostate-specific membrane antigen (PSMA)–targeted radioligand, lutetium-177 (¹⁷⁷Lu)–PSMA-617, improves radiographic progression-free survival (rPFS) vs androgen receptor pathway inhibitor (ARPI) switch and has a favourable safety profile in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on one prior second-generation ARPI, results of the phase III PSMAfore trial have shown.

A multimodal intervention applied in general practice results in a significant decrease in antibiotic prescribing and an increase in guideline adherence among women with uncomplicated urinary tract infection (UTI), a study has shown.

Several forms of serum vitamin A and E were associated with prostate cancer risk, with significant effect modification by smoking and alcohol consumption status, according to an analysis that used data from the Singapore Prostate Cancer Study.

In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).

In a pooled analyses of data from the EAGLE*-2 and EAGLE-3 studies, the investigational, first-in-class, oral, triazaacenaphthylene bactericidal antibiotic gepotidacin showed consistent therapeutic efficacy across key patient subgroups and had an acceptable safety profile in female adults and adolescents with uncomplicated urinary tract infections (uUTI) compared with nitrofurantoin.

In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.